Limits...
Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer.

Zhu W, He J, Chen D, Zhang B, Xu L, Ma H, Liu X, Zhang Y, Le H - PLoS ONE (2014)

Bottom Line: Altered expression of miRNA expression contributes to human carcinogenesis.Receiver operating characteristic (ROC) curve analysis showed that at the optimal cut-off point, the areas under the ROC curve for serum levels of miR-29c and miR-429 were 0.723 and 0.727, respectively, levels which are higher than that of carcinoma embryonic antigen (0.534) in diagnosis of stage I NSCLC.The results of the current study suggest that detection of serum miR-29c and miR-429 expression should be further evaluated as a novel, non-invasive biomarker for early stage NSCLC.

View Article: PubMed Central - PubMed

Affiliation: Department of Joint Immunogenomics Laboratory, Zhoushan Hospital, Zhoushan, Zhejiang, China.

ABSTRACT

Background: Altered expression of miRNA expression contributes to human carcinogenesis. This study was designed to detect aberrant miRNA expressions as a potential biomarker for early detection and prognosis prediction of non-small cell lung cancer (NSCLC).

Methods: miRNA array was used to profile differentially expressed miRNAs and Taqman-based quantitative RT-PCR assays were used to analyze levels of miR-29c, miR-93, and miR-429 expression in NSCLC tissue samples, corresponding normal tissue samples, and serum samples from 70 NSCLC patients as well as in serum samples from 48 healthy controls.

Results: Levels of miR-29c and miR-93 expression were upregulated in NSCLC tissues, while serum levels of miR-29c were also upregulated, but levels of serum miR-429 were decreased in NSCLC. Moreover, the levels of miR-429 expression in NSCLC tissues were associated with those in serum samples. Receiver operating characteristic (ROC) curve analysis showed that at the optimal cut-off point, the areas under the ROC curve for serum levels of miR-29c and miR-429 were 0.723 and 0.727, respectively, levels which are higher than that of carcinoma embryonic antigen (0.534) in diagnosis of stage I NSCLC. In addition, serum levels of miR-429 were associated with poor overall survival of NSCLC patients. Both univariate and multivariate analyses showed that serum miR-429 level was an independent prognostic predictor for NSCLC.

Conclusions: The results of the current study suggest that detection of serum miR-29c and miR-429 expression should be further evaluated as a novel, non-invasive biomarker for early stage NSCLC.

Show MeSH

Related in: MedlinePlus

Differential expression of miRNAs in NSCLC.A, qRT-PCR detection of three miRNAs in 70 NSCLC tumors and the corresponding normal lung tissues. P-values for miR-29c, miR-93, and miR-429 were 0.0408, 0.0444, and 0.3903, respectively, using a paired sample t-test. B, qRT-PCR analysis of serum miRNA levels in serum samples of 70 NSCLC patients vs. 48 healthy controls. P-values of serum miR-29c, miR-93, and miR-429 were 0.0012, 0.9291, and 0.0001, respectively, using an unpaired sample t-test. C, D, E, Association of these miRNA levels between NSCLC tissue and serum samples. Pearson correlation test showed that miR-429 expression in serum was significantly associated with that in NSCLC tissues (r = 0.3578, P = 0.0024), whereas serum levels of miR-29c and miR-93 were not associated with those in NSCLC tissues (r = −0.07877, P = 0.5169 and r = 0.1515, P = 0.2105, respectively). *P<0.05 between groups.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3921142&req=5

pone-0087780-g001: Differential expression of miRNAs in NSCLC.A, qRT-PCR detection of three miRNAs in 70 NSCLC tumors and the corresponding normal lung tissues. P-values for miR-29c, miR-93, and miR-429 were 0.0408, 0.0444, and 0.3903, respectively, using a paired sample t-test. B, qRT-PCR analysis of serum miRNA levels in serum samples of 70 NSCLC patients vs. 48 healthy controls. P-values of serum miR-29c, miR-93, and miR-429 were 0.0012, 0.9291, and 0.0001, respectively, using an unpaired sample t-test. C, D, E, Association of these miRNA levels between NSCLC tissue and serum samples. Pearson correlation test showed that miR-429 expression in serum was significantly associated with that in NSCLC tissues (r = 0.3578, P = 0.0024), whereas serum levels of miR-29c and miR-93 were not associated with those in NSCLC tissues (r = −0.07877, P = 0.5169 and r = 0.1515, P = 0.2105, respectively). *P<0.05 between groups.

Mentions: Based on our miRNA array (Agilent) and validation data, we selected three miRNAs (miR-29c, miR-93, and miR-429) for further study in NSCLC samples. We performed qRT-PCR analysis for these three miRNAs in 70 pairs of NSCLC and corresponding noncancerous lung tissues. Our data showed that levels of miR-29c and miR-93 expression were upregulated in NSCLC tissues compared to the corresponding noncancerous lung tissues (P = 0.0408 and P = 0.0444, respectively), whereas miR-429 levels were not significantly different between NSCLC and noncancerous lung tissues (P = 0.3903, Figure 1A).


Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer.

Zhu W, He J, Chen D, Zhang B, Xu L, Ma H, Liu X, Zhang Y, Le H - PLoS ONE (2014)

Differential expression of miRNAs in NSCLC.A, qRT-PCR detection of three miRNAs in 70 NSCLC tumors and the corresponding normal lung tissues. P-values for miR-29c, miR-93, and miR-429 were 0.0408, 0.0444, and 0.3903, respectively, using a paired sample t-test. B, qRT-PCR analysis of serum miRNA levels in serum samples of 70 NSCLC patients vs. 48 healthy controls. P-values of serum miR-29c, miR-93, and miR-429 were 0.0012, 0.9291, and 0.0001, respectively, using an unpaired sample t-test. C, D, E, Association of these miRNA levels between NSCLC tissue and serum samples. Pearson correlation test showed that miR-429 expression in serum was significantly associated with that in NSCLC tissues (r = 0.3578, P = 0.0024), whereas serum levels of miR-29c and miR-93 were not associated with those in NSCLC tissues (r = −0.07877, P = 0.5169 and r = 0.1515, P = 0.2105, respectively). *P<0.05 between groups.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3921142&req=5

pone-0087780-g001: Differential expression of miRNAs in NSCLC.A, qRT-PCR detection of three miRNAs in 70 NSCLC tumors and the corresponding normal lung tissues. P-values for miR-29c, miR-93, and miR-429 were 0.0408, 0.0444, and 0.3903, respectively, using a paired sample t-test. B, qRT-PCR analysis of serum miRNA levels in serum samples of 70 NSCLC patients vs. 48 healthy controls. P-values of serum miR-29c, miR-93, and miR-429 were 0.0012, 0.9291, and 0.0001, respectively, using an unpaired sample t-test. C, D, E, Association of these miRNA levels between NSCLC tissue and serum samples. Pearson correlation test showed that miR-429 expression in serum was significantly associated with that in NSCLC tissues (r = 0.3578, P = 0.0024), whereas serum levels of miR-29c and miR-93 were not associated with those in NSCLC tissues (r = −0.07877, P = 0.5169 and r = 0.1515, P = 0.2105, respectively). *P<0.05 between groups.
Mentions: Based on our miRNA array (Agilent) and validation data, we selected three miRNAs (miR-29c, miR-93, and miR-429) for further study in NSCLC samples. We performed qRT-PCR analysis for these three miRNAs in 70 pairs of NSCLC and corresponding noncancerous lung tissues. Our data showed that levels of miR-29c and miR-93 expression were upregulated in NSCLC tissues compared to the corresponding noncancerous lung tissues (P = 0.0408 and P = 0.0444, respectively), whereas miR-429 levels were not significantly different between NSCLC and noncancerous lung tissues (P = 0.3903, Figure 1A).

Bottom Line: Altered expression of miRNA expression contributes to human carcinogenesis.Receiver operating characteristic (ROC) curve analysis showed that at the optimal cut-off point, the areas under the ROC curve for serum levels of miR-29c and miR-429 were 0.723 and 0.727, respectively, levels which are higher than that of carcinoma embryonic antigen (0.534) in diagnosis of stage I NSCLC.The results of the current study suggest that detection of serum miR-29c and miR-429 expression should be further evaluated as a novel, non-invasive biomarker for early stage NSCLC.

View Article: PubMed Central - PubMed

Affiliation: Department of Joint Immunogenomics Laboratory, Zhoushan Hospital, Zhoushan, Zhejiang, China.

ABSTRACT

Background: Altered expression of miRNA expression contributes to human carcinogenesis. This study was designed to detect aberrant miRNA expressions as a potential biomarker for early detection and prognosis prediction of non-small cell lung cancer (NSCLC).

Methods: miRNA array was used to profile differentially expressed miRNAs and Taqman-based quantitative RT-PCR assays were used to analyze levels of miR-29c, miR-93, and miR-429 expression in NSCLC tissue samples, corresponding normal tissue samples, and serum samples from 70 NSCLC patients as well as in serum samples from 48 healthy controls.

Results: Levels of miR-29c and miR-93 expression were upregulated in NSCLC tissues, while serum levels of miR-29c were also upregulated, but levels of serum miR-429 were decreased in NSCLC. Moreover, the levels of miR-429 expression in NSCLC tissues were associated with those in serum samples. Receiver operating characteristic (ROC) curve analysis showed that at the optimal cut-off point, the areas under the ROC curve for serum levels of miR-29c and miR-429 were 0.723 and 0.727, respectively, levels which are higher than that of carcinoma embryonic antigen (0.534) in diagnosis of stage I NSCLC. In addition, serum levels of miR-429 were associated with poor overall survival of NSCLC patients. Both univariate and multivariate analyses showed that serum miR-429 level was an independent prognostic predictor for NSCLC.

Conclusions: The results of the current study suggest that detection of serum miR-29c and miR-429 expression should be further evaluated as a novel, non-invasive biomarker for early stage NSCLC.

Show MeSH
Related in: MedlinePlus